A Facebook newsletter looks at how GLP-1 research is moving past diabetes and obesity into cardiovascular and kidney care.
Recap by typeshit. Post by Facebook on Facebook.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
AP reports a federal policy step on peptides that the health secretary has backed. A big development for the gray-market peptide debate.
Post hoc analyses published in the Journal of Clinical Sleep Medicine check how baseline traits shaped tirzepatide results in people with sleep apnea and obesity.
Loading…